Clinical Trial

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Study acronym: ENVY
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 2, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-13; most recent amendment 2025-08-25.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06782139
Lead Sponsor Korea University Anam Hospital
Collaborators: Daewoong Pharmaceutical Co. LTD.
Conditions Obesity and Type 2 Diabetes
Enrollment 30 participants
Start Date 2025-01-20
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-02